Avenue Therapeutics, Inc. (ATXI:NASDAQ) soared at $0.36, a gain of 53.2%. On Wed, Sep 14, 2022, ATXI:NASDAQ hit a New 2-Week High of $0.36. From Wed, Aug 31, 2022, the stock recorded 33.33% Up Days and 50.00% Green Days
The stock spiked on Wed, Sep 14, 2022 at $0.59 with a volume of 65M+.
About Avenue Therapeutics, Inc. (ATXI:NASDAQ)
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of moderate to moderately severe postoperative pain.
Top 10 Gainers:
- AMTD Digital Inc. American Depositary Shares (every five of which represent two Class A) (HKD:NYSE), 311.78%
- Avenue Therapeutics, Inc. (ATXI:NASDAQ), 53.2%
- AMTD International Inc. American Depositary Shares each representing one Class A (AMTD:NYSE), 50%
- Aileron Therapeutics, Inc. (ALRN:NASDAQ), 42.21%
- Dawson Geophysical Company (DWSN:NASDAQ), 40.18%
- Akerna Corp. (KERN:NASDAQ), 26.92%
- Rhythm Pharmaceuticals, Inc. (RYTM:NASDAQ), 24.4%
- SciSparc Ltd. (SPRC:NASDAQ), 23.89%
- ZeroFox Holdings Inc. (ZFOX:NASDAQ), 22.9%
- Magic Empire Global Limited (MEGL:NASDAQ), 21.51%